JHEP Reports,
Год журнала:
2022,
Номер
4(6), С. 100479 - 100479
Опубликована: Март 26, 2022
Lipids
are
a
complex
and
diverse
group
of
molecules
with
crucial
roles
in
many
physiological
processes,
as
well
the
onset,
progression,
maintenance
cancers.
Fatty
acids
cholesterol
building
blocks
lipids,
orchestrating
these
metabolic
processes.
In
liver,
lipid
alterations
prevalent
cause
consequence
chronic
hepatitis
B
C
virus
infections,
alcoholic
hepatitis,
non-alcoholic
fatty
liver
disease
steatohepatitis.
Recent
developments
lipidomics
have
also
revealed
that
dynamic
changes
triacylglycerols,
phospholipids,
sphingolipids,
ceramides,
acids,
involved
development
progression
primary
cancer.
Accordingly,
transcriptional
landscape
metabolism
suggests
carcinogenic
role
increasing
sterol
synthesis.
However,
limited
mechanistic
insights
into
nature
hepatic
lipidome
so
far
hindered
effective
therapies.
The Lancet Oncology,
Год журнала:
2022,
Номер
23(8), С. 995 - 1008
Опубликована: Июль 4, 2022
Cabozantinib
has
shown
clinical
activity
in
combination
with
checkpoint
inhibitors
solid
tumours.
The
COSMIC-312
trial
assessed
cabozantinib
plus
atezolizumab
versus
sorafenib
as
first-line
systemic
treatment
for
advanced
hepatocellular
carcinoma.
Nature reviews. Immunology,
Год журнала:
2021,
Номер
22(7), С. 429 - 443
Опубликована: Ноя. 5, 2021
Non-alcoholic
fatty
liver
disease
(NAFLD)
includes
a
range
of
hepatic
manifestations,
starting
with
steatosis
and
potentially
evolving
towards
non-alcoholic
steatohepatitis
(NASH),
cirrhosis
or
even
hepatocellular
carcinoma.
NAFLD
is
major
health
burden,
its
incidence
increasing
worldwide.
Although
it
primarily
disturbed
metabolism,
involves
several
immune
cell-mediated
inflammatory
processes,
particularly
when
reaching
the
stage
NASH,
at
which
point
inflammation
becomes
integral
to
progression
disease.
The
cell
landscape
diverse
steady
state
further
evolves
during
NASH
direct
consequences
for
severity.
In
this
Review,
we
discuss
current
concepts
related
role
cells
in
onset
NASH.
A
better
understanding
mechanisms
by
contribute
pathogenesis
should
aid
design
innovative
drugs
target
therapeutic
options
are
limited.
(NASH)
serious
chronic
disorder
prevalence
Metabolic
nature,
also
mobilizes
system.
Here,
Huby
Gautier
knowledge
regarding
how
subsets
affect
progression.
